Clinical Endocrinology · 2005 · 45 citations · 21 references
MedicineNephrologyDialysisHemodialysisRenal Replacement TherapyChronic HemodialysisChronic Kidney DiseaseRenal DiseaseRenal Function TestsRenal ImpairmentChronic Renal InsufficiencyHyperprolactinemia In Kidney DiseasePhysiological HyperprolactinemiaProlactin ClearanceProlactin IsoformsReduced Renal ClearanceRenal Endocrine FunctionSandwich Immunoassay Development
OBJECTIVE: Three molecular forms of PRL with molecular weights of 23, 50-60 and > 100 kDa have been defined. The high-molecular-weight forms are called macroprolactin. Different immunoassays produce varyingly elevated results with macroprolactin-containing sera. The kidneys are reported to clear 25% of PRL from the circulation. Hyperprolactinaemia is seen in 20-75% of patients with chronic renal failure (CRF). PRL clearance rate has been reported to be reduced in CRF and the resulting hyperprolactinaemia is due to reduced renal function. PATIENTS: To determine the contribution of macroprolactinaemia to elevated PRL levels in CRF, 91 patients receiving haemodialysis (HD), continuous ambulatory peritoneal dialysis (CAPD) and renal transplantation (RT) therapies and 72 control subjects were included in the study. MEASUREMENTS: Serum PRL levels were measured by a sandwich immunoassay with electrochemical detection. Following polyethylene glycol (PEG) precipitation, recovery ratios were calculated and samples with a recovery of < 50% were identified as having macroprolactin isoforms. RESULTS: The serum and supernatant PRL levels of CRF patients were significantly higher than those of the control group (P < 0.001). The serum PRL levels of HD and CAPD patients were significantly higher than those of the RT patients (P < 0.001). The serum PRL levels of the RT patients and the control group did not differ significantly (P > 0.05). A moderate correlation was found between PRL and creatinine levels (r = 0.609, P < 0.001). CONCLUSIONS: The hyperprolactinaemia seen in renal replacement therapy is not associated with the presence of macroprolactin isoforms but with the decline in renal function.
21
Human prolactin. cDNA structural analysis and evolutionary comparisons.
Nancy E. Cooke, Doris Coit, John Shine et al. · Journal of Biological Chemistry · 1981 · 339 citations · Full text
Macroprolactinemia Revisited: A Study on 106 Patients
Sophie Vallette-Kasic, I. Morange‐Ramos, Ginette Gunz et al. · The Journal of Clinical Endocrinology & Metabolism · 2002 · 214 citations · Full text
Medicine, Endocrinology, Obstetrics +11
GRANT D. SIEVERTSEN, Victoria S. Lim, Charlotte Nakawatase et al. · The Journal of Clinical Endocrinology & Metabolism · 1980 · 210 citations
Medicine, Endocrinology, Physiology +14
Thomas P. Smith, Abdulwahab M. Suliman, Michael Fahie‐Wilson et al. · The Journal of Clinical Endocrinology & Metabolism · 2002 · 193 citations
Michael Fahie‐Wilson, Sara Soule · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · 1997 · 187 citations